Four large drug companies reached a last-minute $260 million legal settlement over their role in the U.S. opioid addiction epidemic, averting the first federal trial that was scheduled to start in Cleveland.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.
The FDA approved San Diego-based Retrophin Inc.’s 100 mg and 300 mg tablets of Thiola EC (tiopronin) to treat cystinuria.
JPMorgan Chase & Co. cut ties with Purdue Pharma LP over the OxyContin maker’s alleged role in the U.S. opioid crisis, forcing the company to find a new bank to manage cash and bill payments, people familiar with the matter said.
New Zealand medical device maker Fisher & Paykel Healthcare Corp. Ltd. and U.S. rival ResMed Inc. agreed to settle patent infringement disputes, ending a three-year tussle that spanned the globe and cost each side millions of dollars in legal fees.
Edwards Lifesciences Corp. paid rival Boston Scientific Corp. $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.
Medtronic will pay a total of nearly $51 million to resolve three legal claims against Covidien Plc and ev3 Inc., two companies that are now part of the Ireland-based medtech company. Medtronic itself had no role in the wrongdoings that resulted in the multi-million fines.
AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.